Novartis Increases Sales but Misses Estimates on Earnings
Novartis (NYS: NVS) reported earnings on July 17. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Novartis beat slightly on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue increased slightly. Non-GAAP earnings per share shrank. GAAP earnings per share dropped.
Margins dropped across the board.
Novartis logged revenue of $14.49 billion. The 10 analysts polled by S&P Capital IQ expected a top line of $14.31 billion on the same basis. GAAP reported sales were the same as the prior-year quarter's.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.30. The five earnings estimates compiled by S&P Capital IQ anticipated $1.32 per share. Non-GAAP EPS of $1.30 for Q2 were 5.8% lower than the prior-year quarter's $1.38 per share. GAAP EPS of $1.01 for Q2 were 9.0% lower than the prior-year quarter's $1.11 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 67.5%, 80 basis points worse than the prior-year quarter. Operating margin was 20.2%, 190 basis points worse than the prior-year quarter. Net margin was 17.1%, 160 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $14.07 billion. On the bottom line, the average EPS estimate is $1.34.
Next year's average estimate for revenue is $57.34 billion. The average EPS estimate is $5.14.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,460 members out of 1,508 rating the stock outperform, and 48 members rating it underperform. Among 442 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 428 give Novartis a green thumbs-up, and 14 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Novartis is outperform, with an average price target of $80.28.
- Add Novartis to My Watchlist.
The article Novartis Increases Sales but Misses Estimates on Earnings originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.